Dopamine-associated neuropsychiatric illnesses, such as schizophrenia and bipolar disorder, seem to be characterized by impairments in the AKT/GSK3β pathway [20,21,22,23,24], while AKT/GSK3β-dependent signaling pathways are involved in the actions of antipsychotics [25,26,27,28,29,30,31,32,33]. This evidence concerns the gene AKT1 and schizophrenia.